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Background: Widely studied for the past 20 years, hepatocyte growth factor (HGF) has been identiﬁed as
a regenerative marker and an important factor in the development and healing of injuries. Antithrombin
III (AT III) is a protein in the blood stream with anti-thrombotic and anti-inﬂammatory properties and has
been used as an adjuvant treatment along with antibiotics in severe sepsis.
Objective: To study the content and properties of HGF in plasma-derived AT III products, and the regen-
erative effect in severe deep ulcer infections.
Methods: Commercial AT III products were analyzed for the presence and biological activity of HGF. One
AT III product containing biologically active HGF was used to treat 18 cases of critical, deep ulcer infec-
tions scheduled for major invasive intervention. The patients were followed up for 6–60 months.
Results: The AT III products contained HGF with different biological activity. No adverse reactions were
observed after local administration of AT III during the study or follow-up period. In 16 of 18 cases no
surgical intervention was needed within the ﬁrst 6 month of inclusion.
Conclusion: AT III products containing biologically active HGF may contribute to regeneration and healing
in severe deep ulcer infections which do not respond adequately to different combinations of antibiotics
alone.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction of chronic liver injury and cancer [4]; and the fact that chronicityAt what point does an acute injury become classiﬁed as chronic,
and why does it become chronic? These are questions for intensive
study. Up to date extensive resources have been invested to rem-
edy symptoms and causes of chronic injuries. Infection is an impor-
tant and widely studied cause of injury [1]. Efﬁcient treatment of
infection results in healing of damaged tissue, and such treatable
damage is considered the result of acute inﬂammation. However
when, despite conventional methods of therapy, injury resists
healing, countless body changes occur causing chronic organ fail-
ure and cancer [2]. Predisposing factors, as the normal atheroscle-
rotic process or the accentuated atherosclerosis in diabetes
mellitus with angiopathy or chronic uremia with atherosclerosis,
are such predisposing factors especially in patients treated with
hemodialysis [3]. Infectious agents difﬁcult to discover by available
methods may cause such chronic damage. Several recent studies
strengthen this notion, such as the discovery of Helicobacter pylori
as the cause of chronic gastritis and cancer; hepatitis as the causerleden 1, 58127 Linköping,
a.lonn@oru.se (J. Lönn).
C-ND license.and damage are inhibited by eliminating infection [5]. Thus the
infectious agent, the body’s response to injury, and several other
factors such as genetic variation and environment may interact,
resulting in the development of chronic injury when damage in
the acute phase remains unresolved [6]. Furthermore, it is known
that various cytokines and growth factors mediate inﬂammatory
responses [7].
Hepatocyte growth factor (HGF) is a cytokine produced during
injury and mediates development, regeneration and healing [8].
Knockout mice lacking the HGF gene cannot survive [9] and low
concentration of circulating HGF during acute infection may indi-
cate an unfavorable prognosis [10]. In an attempt to study the
causes of healing defects during chronic inﬂammation we chose
since 1996 to focus our studies on the presence, properties and
function of HGF in various organs. Skin ulcers may be proper mod-
els to assess organ injury. The damage is visible, the ulcer contam-
inated with bacteria, and the acute and chronic injury well deﬁned.
Therefore we investigated HGF in chronic and acute ulcers [11–13]
and observed that:
a. The HGF receptor was signiﬁcantly up-regulated in chronic
ulcers.
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chronic ulcers.
c. Unlike acute ulcers, secretion from chronic ulcers had no
biological activity in an in vitro model of cell injury.
d. Western blot analysis of ulcer secretion differed in the stud-
ied chronic ulcers compared to controls in the intensity of a
and b-chains of HGF.
e. HGF from chronic ulcer secretion lacked binding afﬁnity to
heparan sulfate proteoglycan (HSPG) in a Surface plasmon
resonance (SPR) system.
f. Local application of HGF to chronic ulcers, with properties of
HGF found in acute ulcers, increased microcirculation.
g. HGF with no biological activity in vitro or no binding afﬁnity
to HSPG in SPR had no signiﬁcant effect on microcirculation
or healing of chronic ulcers despite relevant anti-microbial
treatment.
h. Based on variations in commercially available recombinant
HGF products, endogenous HGF produced in healthy sub-
jects seemed to be appropriate for studies of the HGF effect
in deeper injuries.
Antithrombin III (AT III) is a plasma protein and one of the most
important inhibitor of clotting. It also has anti-inﬂammatory prop-
erties and is administered to patients with congenital or acquired
AT III deﬁciency. The latter indication has been studied widely in
critically ill patients with multiple organ failure [14]. In a review
article by Afshari et al. [15], 20 placebo-controlled trials evaluating
the therapeutic/side effects of AT III in critically ill patients were
surveyed. Thirteen trials consisted of critically ill participants,
mainly with sepsis. The risk of bias was evaluated, and the
different studies were categorized as low/high risk of bias. The re-
sults, combining all trials, showed no statistically signiﬁcant effect
of AT III on mortality. However, the bleeding events signiﬁcantly
increased in AT III-treated patients. Thus, authors of earlier studies
do not recommend AT III substitution to critically ill patients [16].
Although Afshari et al. assessed very detailed and valuable compo-
nents of the studies in their review article, no information about
the AT III product used was provided. Since 2004 we have studied
the products developed during the process of puriﬁcation and
found that AT III products contain HGF. However, the properties
of HGF differed among commercial products.
In the current work different commercial AT III products are
investigated regarding their properties of HGF. The AT III product
with biologically active HGF was used locally in cases of deep skin
and soft tissue injury in which amputation or major surgery was
planned because of therapy failure and life risks. Patients were fol-
lowed up 6–60 months after inclusion. The result was compared to
that of earlier studies in the same ﬁeld (Table 1).2. Materials and methods
2.1. Non-clinical study
2.1.1. AT III products
For the non-clinical studies of AT III the products available
commercially; Atenativ (Pharmacia), Atenativ (Octapharma),Table 1
The effect of the AT III products used as treatment of critically ill patients compared to co
Study Journal
Baudo (1992) Thrombosis Research
Warren (2001) JAMA
Haire (1998) Biology of Blood and Marrow Transplantation
Schorr (2000) European Journal of Clinical Investigation
Waydhas (1998) Trauma, Injury, Infection and Critical CareKybernin-P (Aventis-Behring), Thrombhibin (Immuno AG), and
AT III Baxter (Baxter) were used. Products developed in the pro-
duction process of AT III were received from Octapharma in
2004. The different AT III products were analyzed according to
the contents, binding afﬁnity to ligands and biological activity of
HGF.
2.1.2. Evaluation of the biological activity of HGF in a model of cell
injury
The biological activity of HGF in AT III samples was tested in an
in vitro cell injury assay using transformed mouse skin epithelial
cells (CCL-53.1 cell line). The method has been described in a pre-
vious publication [17]. Shortly, CCl-53.1 cells were grown in Kai-
ghn’s modiﬁcation of Ham’s F-12K medium (ATCC) supplemented
with 15% horse serum and 2.5% fetal bovine serum (Sigma–Aldrich,
St. Louis, MO, USA) in an atmosphere of 5% CO2 and 95% air at
37 C. After the cells reached conﬂuence, they were separated with
non-enzymatic cell dissociation solution (1) (Sigma–Aldrich),
suspended in an F-12K medium with 15% horse serum and 2.5% fe-
tal bovine serum, and inoculated in a 24-well culture plate (Nunc
Brand Products, Roskilde, Denmark). Cells were cultured under
the exact conditions for 24–48 h until they reached conﬂuence.
Then, a line across the conﬂuent monolayer was scraped with a
sterile steel device, detached cells were washed away with PBS
and fresh medium was added to the wells. The area (mm2) of the
square not covered by cells was measured by microscopy (Olym-
pus) and documented in each well. AT III products or PBS was
added (100 ll a0 50 IU/ml AT III or 100 ll PBS as control), and the
cells were incubated at 37 C in a humidiﬁed atmosphere contain-
ing 5% CO2. After 24 and 48 h, the area not covered by a monolayer
was measured again and documented. A decreased area was cate-
gorized as a ‘‘positive’’ effect and no effect as ‘‘negative’’.
2.1.3. SPR measurements and ligand immobilization procedures
To analyze the binding afﬁnity to the different ligands, SPR mea-
surements were conducted at 760 nm in a fully automatic Biacore
2000 instrument (GE-Healthcare GmbH, Uppsala, Sweden)
equipped with four ﬂow cells. Biologically relevant ligands of
HGF (monoclonal anti-HGF antibody (unknown epitope), poly-
clonal antibodies against different parts of HGF, and HGF receptors)
were obtained commercially (Table 2) and immobilized on surface
plasmon resonance (SPR) CM5 chips as previously described [18].
Brieﬂy, the ﬂow cell temperature was 25 C in all experiments.
The sample surfaces were carboxy-methylated dextran CM5 chips
(GE-Healthcare GmbH, Uppsala, Sweden). Coupling of ligands to
the carboxylic acid groups of the dextran hydrogel was carried
out by conventional carbodiimide chemistry using 200 mM EDC
(N-ethyl-N0-(3-diethylaminopropyl) carbodiimide) and 50 mM
NHS (N-hydroxysuccinimide). Activation time was 7 min, followed
by a 7 min ligand injection. Deactivation of the remaining active
esters was performed by a 7 min injection of ethanolamine/hydro-
chloride at pH 8.5. A ﬂow rate of 5 ll/min was used during immo-
bilization. The ligands (Table 2) were diluted in 10 mM acetate
buffer at a pH below the protein’s isoelectric point, thus enhancing
the electrostatic interactions between the dextran matrix and the
ligands. The contact time was 7 min, which resulted in levels ofntrols in other studies. The outcome measured is overall mortality.
Risk ratio AT III product
0.25 Thrombhibin (Immuno AG)
0.96 Kybernin-P (Aventis-Behring)
0.67 AT III Baxter (Baxter)
1.08 Atenativ, Pharmacia (Octapharma)
2.00 Atenativ, Pharmacia (Octapharma)
Table 2
The ligands used for binding afﬁnity analysis in SPR.
Immobilized ligands in SPR Source/product number Code Goal of investigation
Monoclonal anti-HGF ab R&D Systems/MAB294 MN Determine amount of HGF
Recombinant HGF receptor (c-met)/fc chimera R&D Systems/358 MT c-Met Analyze HGF binding to c-met receptor
Heparan sulfate proteoglycan Sigma–Aldrich/H4777 HSPG Analyze HGF binding to HSPGP 100 lg/ml
Polyclonal anti-HGF ab, afﬁnity isolated Sigma–Aldrich/HH0652 PK Determine amount of HGF
H-170 rabbit polyclonal ab Santa Cruz/sc-13,087 H-170 Bind amino acids 1–170 of human HGF
N-19 afﬁnity-puriﬁed goat polyclonal ab Santa Cruz/sc-1356 N-19 Peptide mapping at the N-terminus of human HGF
N-17 afﬁnity-puriﬁed goat polyclonal ab Santa Cruz/sc-1357 N-17 Peptide mapping at the N-terminus of human HGFa
C-20 afﬁnity-puriﬁed goat polyclonal ab Santa Cruz/sc-1358 C-20 Peptide mapping at the C-terminus of human HGFa
H-145 rabbit polyclonal ab Santa Cruz/sc-7949 H-145 Bind amino acids 32–176 of human HGFa
D-19 goat polyclonal IgG Santa Cruz/Sc-34,461 D-19 Epitope mapping in an internal region of human HGF
S-16 goat polyclonal IgG Santa Cruz/Sc-34,462 S-16 Epitope mapping in an internal region of human HGF
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After deactivation, the surfaces were washed with ﬁve subsequent
1 min injections of 5 mM glycine buffer, pH 2.0, with 1 M NaCl
(regeneration buffer). One of the ﬂow cells was used as a control
to monitor the response due to the interaction of HGF with the car-
boxymethylated dextran matrix. This ﬂow cell was treated in the
same way as the others during the immobilization procedure,
but the ligand immobilization step was omitted.
AT III products were reconstituted and analyzed at different
concentrations. Physiological NaCl (9 mg/ml), distilled water (B.
Braun Medical AB, Bromma, Sweden), PBS (pH 7.4, Apoteket AB,
Umeå, Sweden), and HBS-EP (0.01 M HEPES, pH 7.4, 0.15 M NaCl,
3 mM EDTA, 0.005% surfactant P20; GE-Healthcare GmbH, Uppsala,
Sweden) were used as dilution and running buffers. A 1:1 mixture
of 1 M NaCl + 10 mM glycine, pH 2, was used as regeneration buf-
fer. The presented SPR data was extracted from the Biacore sensor-
grams after the injections were completed, i.e. during the analyte
dissociation phase. One Biacore RU corresponds to a surface con-
centration of 1 pg protein per mm2 [19]. The binding of HGF to li-
gands was tested in AT III samples after reconstitution in different
dilutions. A positive and a negative control were included at the
beginning and at the end of each run to conﬁrm the reliability of
surfaces.
The following experiments were analyzed in SPR:
– Epitope mapping: AT III Baxter 50 IU/ml (diluted in a ratio of 1:1
with PBS) was injected for 3 min three times until further injec-
tions did not add to the signal intensity (all binding sites were
engaged) and this level was set as baseline. Epitope-speciﬁc
antibodies against different parts of HGF (Table 2) were then
injected for 3 min, and the signal intensity in each channel
immobilized with c-Met, monoclonal anti-HGF antibody (MN),
and HSPG was recorded [20].
– Stability of fractions: The effect of time on the response was
tested by continuous analysis of binding over time on the same
chip and during the same run.
– Afﬁnity puriﬁed AT III products: The afﬁnity chromatography
columns (Hi-trap GE Healthcare) were immobilized with HSPG
according to the manufacturer’s instructions. The AT III samples
(50 IU/ml) were reconstituted and diluted in PBS (pH 7.4) in a
ratio of 1:1 and injected into the column. 5 mM glycine buffer
pH 2.0 with 1 M NaCl was used as elution buffer. Thereafter
the afﬁnity of samples (start sample as well as eluent from
the column) to immobilized ligands in the SPR system was
tested.
– Incubation of AT III with glycosaminoglycan dextran sulfate
(DS) or fragmin: AT III (50 IU/ml) containing biologically active
HGF was incubated with DS (10 mg/ml MQ; Sigma Aldrich), or
12 IU/ml AT III with fragmin (0.02-100 IU a´25 000 IU/ml; Pﬁzer
AB, Sollentuna, Sweden), at RT for 30 min. The binding response
to HSPG and MN was measured in SPR.– Incubation of AT III with bacteria: AT III that contained biolog-
ically active HGF was diluted in a ratio of 1:5 with PBS and kept
at room temperature for 48 h with or without addition of aero-
bic bacteria (Enterococcus faecalis, Enterobacter cloacae, Staphy-
lococcus aureus, Escherichia coli, Staphylococcus epidermis) or
anaerobic bacteria (Porphyromonas gingivalis). The binding
afﬁnity to MN and HSPG was assessed in SPR.
2.1.4. ELISA
The HGF concentration in the AT III samples (Atenativ and AT III
Baxter) was determined using a commercial ELISA kit (Quantikine
Human HGF immunoassay, minimum detectable limit: 0.04 ng/
mL; R&D Systems) according to the manufacturer’s instructions.
The measurements were performed in duplicate at 450 nm using
an ELISA reader (Expert 96; Asys Hitech GmbH, Eugendorf, Aus-
tria), and calibrated using the recombinant human HGF reference
samples that were provided in the ELISA kit.
2.1.5. Western blotting
The AT III products were diluted in Krebs–Ringer Glucose Buf-
fer; in a ratio of 1:11 (KRG; consisted of 120 mM NaCl, 4.9 mM
KCl, 1.2 mM MgSO4, 1.7 mM KH2PO4, 8.3 mM Na2HPO4, and
10 mM glucose, pH 7.3), and thereafter heated in a Laemmli sam-
ple buffer and 2-Mercaptoethanol (98 C for 5 min) at a ratio of
1:1 to denature and reduce the proteins. The proteins were sepa-
rated using standard sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE containing 12% Tris or any Kd gel)
and electrotransferred to a polyvinylidene diﬂuoride membrane.
Unspeciﬁc binding was blocked by incubating the membranes in
5% milk-Tris-buffer saline (TBS; consisted of 25 mM Tris base,
150 mM NaCl, 2 mM KCl pH 7.4, and 0.1% Tween-20) for 1 h at
RT prior to incubation with a goat polyclonal anti-HGF antibody
(1:1000; AF-294-NA) for 1 h at RT. The membranes were thereafter
incubated with a polyclonal HRP-conjugated donkey anti-goat
antibody (1:1000; HAF109). Recombinant HGF (294-HA; R&D sys-
tems, Minneapolis, MN, USA) was used as a positive control.
2.2. Clinical part of the study
2.2.1. AT III product used in deep ulcer infections
AT III found to contain HGF with binding afﬁnity to both MN
and HSPG in the SPR system and showed biological activity on
CCL-53.1 cells, was used in the clinical part of the study.
2.2.2. Study subjects and treatment
The study subjects were enrolled from patients admitted to
hospital because of deep ulcer infection in need of systemic antibi-
otic treatment and invasive interventions. However, therapy had
failed to resolve the infection and major surgery was planned.
None of the included cases were suffering from severe sepsis
and/or multiple organ dysfunctions at the time of inclusion. The
Fig. 1. Western blot analysis of the AT III products. The AT III products;
Thrombhibin (Immuno AG; 1), Kybernin-P (Aventis-Behring; 2), Atenativ
(Octapharma; 3) and AT III Baxter (Baxter; 4) were reduced by heating 98 C,
5 min in Laemmli sample buffer, and the electrophoretically separated proteins
were detected by western blotting using a goat polyclonal anti-HGF antibody
(1:1000) and a polyclonal HRP-conjugated donkey anti-goat antibody (1:1000).
Recombinant HGF (rHGF) was used as a positive control.
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took therapeutic responsibility for patients, receiving 100 ll of
the AT III product (50 IU/ml) containing biologically active HGF
locally once daily together with antibiotics for 5–7 days. In cases
where the process of deterioration continued after inclusion abrupt
surgery was planned. In other cases patients were treated and fol-
lowed up by the study group for at least 6 months. Occlusive or
semi-occlusive bandages containing plastic material were strictly
prohibited during the study period of 6 months if the ulcer was
not already closed. Choice of antibiotics was based on bacterial cul-
ture results of the wound as well as clinical judgment based on
appearance, discharge, smell, and circulation. Eighteen patients
were included and followed the study protocol from 2005 in an
open prospective study. Four patients were included twice upon
patients’ request to inhibit severe progress of already healed ul-
cers. The local ethical committee in Linköping, Sweden, approved
the study and a written consent was obtained from all study
subjects.
2.3. Statistical analysis
Data were statistically analyzed by paired and un-paired
Student t tests by using Graph Pad Prism version 5.0. P 6 0.05
was considered statistically signiﬁcant Representative experiments
are presented.3. Results
3.1. The presence and biological activity of HGF in AT III products
AT III products; AT III Baxter, Atenativ, Kybernin-P, and Throm-
bhibin used in previous studies analyzing the effect of AT III in crit-
ically ill patients (Table 1) were examined in the present study
regarding the HGF containment, concentration and biological
activity.
Beside the ELISA measurements (Table 3), the presence of HGF
in the AT III products was also conﬁrmed by western blotting
(Fig. 1). AT III Baxter and Thrombhibin, both from Baxter, showed
several bands, compared to Atenativ and Kybernin-P that did not
contain biologically active HGF and showed bands of about
60 kDa in western blotting.
In the in vitro model of cell injury, the addition of 100 ll AT III
Baxter or Thrombhibin (50 IU/ml) caused a decrease of the injured
area and was considered to contain biologically active HGF, while
Atenativ and Kybernin-P did not show any effect on the cultured
cells (Table 3), neither the negative control PBS.
AT III Baxter and Thrombhibin also showed the presence of HGF
with a high binding afﬁnity to HSPG, as well as monoclonal anti-
HGF antibodies in SPR (Table 3). The afﬁnity of HGF to the ligands
in the SPR system did not decrease signiﬁcantly when incubated
overnight in RT or during several SPR runs (P = 9) thus indicating
the stability of HGF in the AT III products. After puriﬁcation in
the HSPG-bound afﬁnity column the eluent had still afﬁnity to-
wards HSPG in the SPR system.Table 3
AT III products and responses in SPR, ELISA and on cultured cells. Afﬁnity chromatograph
MN anti-HGF SPR (RU)
Atenativ 50 IU/ml (1:1 PBS) 1762
Atenativ afﬁnity puriﬁed in HSPG column 11
Kybernin-P 50 IU/ml (1:1 PBS) 731
Thrombhibin, (Baxter) 50 IU/ml (1:1 PBS) 3055
Antithrombin III Baxter 50 IU/ml (1:1 PBS) 1053
Antithrombin III Baxter afﬁnity puriﬁed in HSPG column 158By epitope mapping it was found that when binding (HGF in) AT
III Baxter to ligands in SPR without a following wash, the speciﬁc
anti-HGF antibodies H-170 (binds to amino acids 1–170 of human
HGFb), H-145 (binds to amino acids 32–176 of human HGFa), S-16
(binds to an internal region of human HGFb) (Table 2) that sequen-
tially was run over the sample, did not bind to the AT III sample in
all immobilized channels (C-met, MN and HSPG) (P < 0.0001)
(Table 4). This indicates that these peptides, which the antibodies
are directed against, are involved in the binding afﬁnity of biolog-
ical active HGF in the AT III product. Furthermore, the addition of
glycosaminoglycan dextran sulfate or fragmin to the AT III product
caused reduced binding to HSPG and MN (P < 0.00001) (Tables 5
and 6) in SPR.
The effect of different bacteria on AT III product that contained
biologically active HGF (AT III Baxter) was analyzed by SPR after
incubation with bacteria. Several bacterial species, especially the
anaerobic bacterium P. gingivalis, decreased the binding afﬁnity
to MN and HSPG in SPR (Table 7).
3.2. The clinical study of patients with critical deep ulcer infections
After inclusion all patients continued the study after the ﬁfth
day of the treatment (Table 8), thus the situation of injury was im-
proved and conservative therapy continued. The end point of the
study was total closure of the ulcer within 6 months. Inclusion of
patients from 2005 gave the advantage of meeting and following
the patients for several years. No signs of adverse reactions or
malignancy were observed during the study or within the follow-
up period. Fresh bleeding from chronic infectious injury was seen
in the ﬁrst week and predicted a favorable outcome. During the
study occlusive bandaging was strictly prohibited and beside from
washing with tap water and mild soap and sterile cotton bandages
no other local treatments or active bandages were used. In two
patients (Nos. 3 and 13, Table 8) in spite of partial improvement,y and ELISA were performed on Atenativ and AT III Baxter.
HSPG SPR (RU) Biological activity on CCL-53.1 cells ELISA
53 Negative 3.0 ng per 50 IU
9 nd nd
2 Negative nd
2386 Positive nd
865 Positive 5.5 ng per 500 IU
86 nd nd
Table 4
Afﬁnity to epitope-speciﬁc antibodies. AT III Baxter (50 IU/ml) was diluted in a ratio of 1:1 in PBS and was injected into the SPR channel, with immobilized C-met, monoclonal-
anti-HGF ab (MN) and HSPG, several times until binding sites were saturated. This value was then set as baseline. Epitope-speciﬁc antibodies (diluted in PBS 1:5) against HGF
were then injected into the channel, and the afﬁnity of antibody for the HGF + ligand complex was measured in response units (RU). An un-immobilized channel was used as
control of the binding to the dextran-surface of the chip.
Samples and antibodies C-Met (RU) MN anti-HGF ab (RU) HSPG (RU) Control (RU)
AT III Baxter 859 490 395 272
H-145 38 23 15 4
C-20 70 36 160 142
N-19 272 223 353 329
H-170 32 18 14 4
N-17 88 79 163 175
S-16 23 10 2 11
D-19 86 84 149 166
Table 5
The afﬁnity of AT III products (50 IU/ml) to ligands decreased after addition of dextran sulfate (DS, 10 mg/ml) to the samples.
H 170 (RU) N19 (RU) C-20 (RU) HSPG (RU)
DS + PBS 22 93 100 7
Atenativ + PBS 70 62 663 58
Atenativ + DS 39 114 50 6
AT III Baxter + PBS 1550 1563 3394 214
AT III Baxter + DS 37 109 36 21
Table 6
AT III products incubated with fragmin (25,000 IU/ml) and the effect on afﬁnity of
HGF in AT III to ligands analyzed with SPR (in response units, RU).
MN anti-HGF ab (RU) HSPG (RU)
Thrombhibin 1.2 IU/50 ll (1:1 PBS) 1616 1111
+0.02 IU fragmin 971 533
+0.1 IU fragmin 10.5 2.7
+20 IU fragmin 4.2 15
+40 IU fragmin 12 3
+60 IU fragmin 10 2
+80 IU fragmin 10 1
+100 IU fragmin 9 1
Kybernin-P 1.2 IU/50 ll (1:1 PBS) 2.3 3
Kybernin-P 1.2 IU + 0.02 IU fragmin 3 3
Table 7
Incubation of AT III product (AT III Baxter), or physiological (9 mg/ml) NaCl, with
different bacteria and binding afﬁnity to ligands in SPR (measured in response units,
RU).
Bacteria HSPG SPR (RU) MN anti-HGF ab SPR (RU)
E. faecalis in NaCl 1.6 47
E. faecalis in AT III 59 67
Enter. cloacae in NaCl 0 20
Enter. cloacae in AT III 90 168
E. coli in NaCl 1.4 0
E. coli in AT III 48 131
P. aeruginosa in NaCl 42 21
P. aeruginosa AT III 26 66
S. aureus in NaCl 3 0
S. aureus in AT III 30 0
S. epidermis in NaCl 3 40
S. epidermis in AT III 14 121
P. gingivalis in NaCl 6 19
P. gingivalis in AT III 4 1
AT III 1:5 in NaCl 45 134
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considered as therapy failure. In the remainder the primary ulcer,
and in three patients the new ulcers, were healed within 6 months
(Nos. 4, 8 and 18, Table 8). The ulcers relapsed in eight cases fol-
lowing the completed study period.
In spite of the growth of gram-negative bacteria in the cultures
of some patients, they received wide range antibiotics during theﬁrst week of treatment intravenously, but we chose to focus on
gram-positive bacteria with oral treatment in the majority of cases
(Table 8), and still the ulcer situation improved. Below we present
four case reports to describe the medical history in greater detail.
3.2.1. Patient No. 3
Patient No. 3 (Table 8) was a woman born in 1959, a heavy smo-
ker with type 1 diabetes mellitus, and a chronic venous ulcer and
ulcer with necrosis in digits (Dig) II–IIII of the right foot since
1998. She was under oral antibiotic treatment because of X-ray-
veriﬁed osteitis of the right foot and underwent partial amputation
in 1999. She had developed a ﬁstula at the amputation area and ul-
cer revisions were performed several times. She was admitted on
January 4th 2006 to the Department of Infectious Diseases because
of septicemia with growth of Pasteurella multocida in cultures
taken from blood and ulcer secretion. She received ampicillin intra-
venously and beta-blockers because of progressing heart failure,
and acute amputation of the right leg below the knee was planned.
She was included on the study January 19th 2006. Antibiotic treat-
ment was changed to piperacillin–tazobactam and the patient re-
ceived AT III 100 ll (50 IU/ml) injected in the ﬁstula daily. After
the third day of treatment the ﬁstula started bleeding. The patient
was dismissed the 19th of January with ampicillin–clavulanic
acid + ciproﬂoxacin orally. However, she had several episodes of fe-
ver of unknown origin with negative cultures. The ﬁstula on her
right foot was closed but the patient developed skin necrosis at
the top of Dig I of the right foot and along the lateral side of the
foot. She underwent ulcer revision in May 2006 and amputation
of Dig I and V in August 2006, and foot amputation on the left side
2008. She developed a hemolytic uremic syndrome, renal failure,
endocarditis, blindness, and died in septicemia caused by E. faecalis
in August 2008.
3.2.2. Patient No. 8
Patient No. 8 (Table 8) was an 80-year-old woman with diabe-
tes mellitus from 2002, cerebrovascular infarction, thyroid cancer,
atrial ﬁbrillation, and critical ischemia in both lower extremities
veriﬁed by arterial duplex and angiography 2009. X-ray veriﬁed
osteomyelitis of Dig I. The cultures from an ulcer beneath the right
leg and foot yielded Pseudomonas aeruginosa, Morganella morganii
and Coliform bacteria. She had received the oral antibiotics
Table 8
Study subjects’ with inclusion, location of deep injury, culture results from ulcer secretion, antibiotic treatment and outcome.
Born/sex/
inclusion
year
Major disease/planned
major surgery
Deep ulcer location Cultures Antibiotics Outcome
1 1939/
female/
2005
Diabetes type 2 edema,
blisters
Lower leg bilateral E. coli + CNS Ampicillin–clavulanic acid
oral
Healed 2005 new
blisters 2011
2 1948/
female/
2006
Diabetes, hemodialysis/
amputation
Osteomyelitis foot
bilateral
S. aureus, group G Streptococci Clindamycin intravenously/
Clindamycin oral
Healed 2006, dead
2008 in pulmonary
edema
3 1959/
female/
2006
Diabetes type 1, Chronic
renal failure/amputation
Osteomyelitis and
ﬁstula right foot
Pasteurella multocida, enterobacter,
pseudomonas
Piperacillin–tazobactam iv,
Ciproﬂoxacin oral
Fistula healed but
continued ulcer,
dead 2009 in E.
faecalis septicemia
4 1939/
male/
2006, 2008
Diabetes type 1,
hypertension/amputation
Osteomyelitis MTP 1
therapy failure
S. aureus + E. faecalis Piperacillin–tazobactam iv/
Ampicillin–clavulanic
acid + metronidazole oral
Healed 2006, relapse
2008, healed, relapse
2011 amputation
5 1948/
male/2007
Diabetes type 2/revision Osteomyelitis Dig V S. aureus Ceftriaxon iv/Clindamycin
oral
Healed 2007, relapse
2010
6 1939/
female/
2007
Heavy smoker,
Trombangitis oblitirans/
amputation
Osteomyelitis Dig V S. lugdunesis Ampicillin–
clavulanacid + Moxiﬂoxacin
oral
Healed 2007, relapse
2011
7 1931/
female/
2009
Seropositive Rheumatoid
arthritis (RA), several joint
prosthesis, severe
ischemia left leg/
amputation
Necrosis, deep ulcer
circumference left leg
E. faecalis + E. coli Piperacillin–tazobactam iv/
ampicillin–clavulanic
acid + metronidazole oral
Healed 2009, relapse
2011, amputation
under knee
8 1931/
female/
2009, 2010
Diabetes type 2, thyroid
cancer, cerebro vascular
accident/amputation
Arterial ischemia foot,
osteomyelitis, necrosis
S. aureus + E. faecalis, gram negative
bacteria
Cefotaxim + clindamycin iv,
ampicillin–clavulanic acid
oral
Healed 2009,
contralateral foot
ischemia 2010,
healed 2010
9 1992/
male/2009
Tympanic membrane
perforation,
myringoplastic 2008/
major surgery
Chronic deep infection
ear canal
MDRa, Burkholderia cepacia Trimetoprim
sulfamethoxazole oral
Healed 2009
10 1942/
female/
2010
Smoker, spondylolisthesis,
colitis/surgery
Postoperative
infection, Fusion L4-S1
S. aureus + E. faecalis Piperacillin–tazobactam iv/
ampicillin–clavulanic acid
oral
Healed 2010
11 1941/
male/2010
Tibialis fracture 1970,
osteotomy/plastic surgery
Tibialis ﬁstula
osteomyelitis
S. aureus, group B. Strep Moxiﬂoxacin + rifampicin
oral
Healed radiologic
2010, new ﬁstula
2011, healed
12 1943/
female/
2010
Seropositive RA, several
prosthesis, arterial
occlusion right leg 2008/
amputation
Chronic
osteomyelitis + ﬁstula
right lateral Malleolus
Corynebacterium + peptostreptococcus Piperacillin–tazobactam iv/
Fucidinacid + Metronidazole
oral
Healed 2010,
13 1939/
male/2010
Diabetes, RA,
immunosupp. Aortic
valvular stenosis/
reamputation
Osteomyelitis Dig I, II
right foot. sepsis,
therapy failure
S. aureus + E. faecalis Piperacillin–tazobactam iv/
Moxiﬂoxacin
Clinically improved
2010, relapse 2011,
dead 2011 in
cerebrovascular
infarction
14 1954/
male/2010
Diabetes type 2/
amputation
Osteomyelitis Dig III
right foot, necrosis
Group G. Strep Ertapenem iv/Clindamycin
oral
Healed 2010
15 1957/
male/2010
Diabetes, hypertoni
Abscess left heel 2009/
amputation
Deep ulcer and osteitis
left tuber calcanei,
therapy failure
S. aureus + E. faecalis +Morganella
morganii
Ampicillin–Clavulanic acid
oral
Improved slowly,
healed 2011
16 1950/
male/
2010, 2011
Necrotiserande fascitis
right leg 2000 Left knee
prosthesis planned
Deep ulcer lateral
right foot
S. aureus + E. faecalis + P. aeruginosa Ampicillin–
clavulanacid + Rifampicin
oral
Healed 2010, left
knee prosthesis 2010
relapse ulcer 2011
17 1955/
female/
2011
Heavy smoker, sepsis,
empyema 2010
Osteomyelitis right
leg, therapy failure
MDR P. aeruginosa Ceftazidim iv Healed 2011,
relapsed 2011,
healed
18 1957/
male/May
2011,
November
2011
Diabetes, alcohol cirrhosis,
myocardial infarction,
renal failure/amputation
Foot osteomyelitis ESBLb, E. faecalis, MDR Acinetobacter,
S. aureus
Piperacillin–tazobactam iv/
Ampicillin–clavulanic acid
oral
Healed 2011, new
ulcers same foot.
Healed 2011
a Multi-drug resistant.
b Extended spectrum betalactamase.
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tion deteriorated rapidly. New cultures showed growth of cipro-
ﬂoxacin resistant P. aeruginosa, S. aureus and Stenotrophomonas.
She received intravenous antibiotics piperacillin–tazobactam and
ceftazidim for 2 weeks and the symptoms were relieved. She was
admitted to the Department of Infectious Diseases with symptomsof necrosis (Dig I), intense pain, and edema of the right leg on Sep-
tember 29th 2009 and acute amputation was planned. She was in-
cluded in this study on the same day and initially received
cefotaxim + clindamycin changed to piperacillin + tazobactam on
September 30th + AT III locally on the ulcers of the lower part of
the leg and toes. Continuous improvement followed and the
Fig. 2. An example of the process of treatment of one patient (patient No. 8, Table 8), included the ﬁrst time on September 24th 2009, and the second time on March 15th
2010.
484 J. Lönn et al. / Cytokine 60 (2012) 478–486patient was discharged on October 6th 2011 with ampicillin–clav-
ulanic acid + metronidazole orally. Ulcers healed within 2 months
together with self-amputation of black toes (Dig I–II). In April
2010 the left foot showed signs of critically decreased arterial
circulation. She was admitted to the Department of Infectious Dis-
eases on October 12th 2010 and received piperacillin–tazobactam.
The orthopedic consultant recommended amputation. She was in-
cluded in the study again and treated with meropenem + AT III and
was dismissed on October 29th 2010 with continued oral antibiot-
ics ampicillin + trimethoprim–sulfamethoxazole. The ulcers healed
and the patient had no further relapses. The blood glucose level
normalized without treatment and she spontaneously returned
to sinus rhythm (Fig. 2).
3.2.3. Patient No. 9
Patient No. 9 (Table 8) was a 19-year-old man with a long deep
infection of several months duration in the ear canal. The cultures
yielded growth of Burkholdera cepasia that developed resistance
successively during on-going antibiotic treatment. At the time of
inclusion the bacteria were resistant to piperacillin–tazobactam,
ertapenem, ciproﬂoxacin, ceftazidim, tobramycin, meropenem,
imipenem, azteronam, cefotaxim, ampicillin clavulanic acid, ticar-
cillin, and polymixin B. There was a profuse purulent discharge de-
spite several weeks of intravenous antibiotic treatment. Surgery
might have caused a massive tissue loss. The patient was included
in the study in October 2009 and treated with a combination of tri-
metoprim sulfamethoxazole orally and local application of AT III in
the ear canal. Antibiotic treatment continued for 2 months.
Cultures were negative after 1 week, and no relapse has been doc-
umented since.
3.2.4. Patient No. 18
Patient No. 18 (Table 8) was a 56-year-old man with type 2 dia-
betes mellitus, alcoholic cirrhosis and myocardial infarction that
was admitted to hospital in Thailand because of a deep left foot ul-
cer. He underwent several revisional surgeries. He was admitted to
the Department of Infectious Diseases, University Hospital of
Linköping, Sweden April 27th 2011 and Cultures taken on arrivalyielded growth of E. coli and the patient was treated with cefo-
taxim intravenously for 1 week. Rapid deterioration was observed
and the patient underwent revisional surgery and deep cultures
were taken on May 2nd 2011. Necrotic tissue and osteomyelitis
were observed. In spite of treatment by vacuum pump and intrave-
nous antibiotics there was no improvement. A second operation
was performed on May 20th with amputation of the second meta-
tarsal head of the left foot. Amputation at a higher level was
planned in case of failure. Deep cultures yielded growth of ex-
tended spectrum betalactamase (ESBL) E. coli, multiple drug resis-
tant Acinetobacter, E. faecalis and S. aureus. The patient received
polymyxin E (Colistin) intravenously + oxacillin and fusidic acid or-
ally. He developed an acute renal failure and the treatment was
interrupted on May 25th. He was included in the study on the
same day receiving piperacillin–tazobactam + AT III for 5 days
and he was discharged on June 5th 2011 with ampicillin–clavu-
lanic acid. The ulcer cultures again yielded growth of E. coli ESBL
and Acinetobacter but the healing process continued. The ulcer
healed but he acquired new deep ulcers on the ﬁrst metatarsal
head of the same foot after antibiotic treatment was interrupted
in October 2011. New treatment with AT III Baxter, and ampicil-
lin–clavulanic acid resulted in the rapid regression of new ulcers.
4. Discussion
The current work is not just a clinical study but also case reports
presenting the concerns of physicians facing the advanced stages of
chronic disease in patients where conventional therapies had failed
and surgery was planned, not to cure but to postpone the acute
phase of deterioration. This was the case with long, unplanned fol-
low-up periods of several years in the study protocol, which oc-
curred because contacts between the researcher and the study
subjects led to relationships formed between patient and physi-
cian. This might be the most important bias of the study, but the
study group had in fact met so many patients with a critical status
that could not be included in the study and undergone numerous
revisions including salami-amputations, until their deaths. So this
study report cases of therapy failure in spite of several treatment
J. Lönn et al. / Cytokine 60 (2012) 478–486 485attempts, however, after treatment with AT III containing biologi-
cally active HGF most patients survived, but the majority of pa-
tients suffered relapses.
Our group have previously studied recombinant HGF, kindly
provided from Professor Nakamura, in local applications to chronic
ulcers and positive results were obtained with the objective sign of
increased microcirculation in the ulcerous area [13]. This recombi-
nant HGF showed the same properties as endogenous HGF found in
ulcerous secretion from acute ulcers with a high afﬁnity for HSPG
in an SPR system and biological activity in a model of cell injury in
mouse skin epithelial cells (CCL-53.1), accelerated hair growth in
mice, and two separate bands resembling a and b chains of HGF
in western blot [11]. However, later studies by our group using
commercial recombinant HGF showed no increased regeneration
or healing, and further studies of these products showed that one
or several of the named properties were missing [12]. Thus, we
decided to use puriﬁed HGF from healthy blood. The products, ob-
tained during Cohn fractioning of blood for the production of AT III,
was hypothesized to contain HGF. This was the case after the
examination of fractions during the process of purifying blood for
the production of AT III.
The presence of HGF in the AT III products was conﬁrmed with
ELISA, Western blot and SPR. However, the biological activity and
stability of HGF could be assessed by its afﬁnity to HSPG [18].
Two of the AT III products showed high binding afﬁnity to HSPG
and also cell growth in the model of cell injury, and were therefore
considered to contain biologically active HGF. The sites on the HGF
molecule that interacts with the receptors have been studied pre-
viously [21]. Epitope mapping of the AT III products containing bio-
logically active HGF in the present study showed that they, after
interaction of HGF in AT III products to receptors (c-Met and HSPG)
in the SPR system, did not bind to antibodies, directed against spe-
ciﬁc epitopes in a and b chains of HGF, that subsequently were run
over the sample, indicating that both chains of HGF are involved in
the interaction of HGF with receptors. Thus attenuation of bands (a
and b chains) of HGF by strains, such as those found during the pro-
cess of virus inactivation during the production of some AT III
products, may result in the inactivation of HGF. In the western blot
analysis the AT III products with biologically active HGF presented
several bands, compared to the products without biologically ac-
tive HGF (Fig. 1), these may be both a and b chains, and pro-HGF
that are bigger in size. When incubating AT III products with dex-
tran sulfate, a glycosaminoglycan analog, the binding response to
ligands decreased, especially in AT III containing biologically active
HGF (Table 6). This shows that the binding site for HSPG, which
dextran sulfate occupies during the incubation, is necessary for
the binding of AT III to HSPG and the biological activity (Table 5).
Likewise, incubation with fragmin, a low molecular weight heparin
which also belongs to the glycosaminoglycan family, decreased the
binding response proportionally with increased concentration. In a
clinical study by Warren et al. [16] it was shown that concomitant
administration of heparin, even when given in relatively low doses
as unfractionated or lowmolecular weight heparin, interacted with
AT III treatment and the patients with severe sepsis did not re-
spond to the AT III treatment and it was associated with increased
risk of hemorrhage.
Elimination of bacteria in chronic injuries is an important step
in therapy response [22]. However, not one but several bacteria
contaminated ulcers. The question is which bacteria we should fo-
cus treatment on? The pathogenic bacteria in ulcers are apparently
not those that grow ﬁrst. Culture results and the ultimately bene-
ﬁcial antibiotic regime chosen were shown by following diseases
and their outcome in included patients (Table 8). The results indi-
cate the importance of recognizing the symptom-producing bacte-
ria in the ulcer. Improvements may partly depend on the fact that
we avoided occlusive/semi-occlusive bandages and washed awaythe contaminating bacteria. Interestingly, P. gingivalis that is an eti-
ological agent strongly associated with periodontal disease [23]
and correlates with numerous inﬂammatory disorders, such as car-
diovascular and rheumatic disease. The bacterium was found to
eliminate the biologic activity of HGF. P. gingivalis express a broad
range of virulence factors, such as cysteine proteinases (gingipains)
that could cleave proteins of the host [24] and perhaps this could
be one mechanism in the reduced biological activity of HGF.
Some study patients suffered from serious arterial insufﬁciency
in the lower extremity (patient Nos. 6, 7, 8 and 12 in Table 8) in
addition to decreased microcirculation. Still, they showed favor-
able results from the study intervention. HGF is a known angioge-
netic factor [25] and we have shown increased microcirculation in
ulcers after the administration of recombinant HGF [13]. However,
AT III is an anti-coagulatory factor and the combination of AT III
and biologically active HGF may have a positive effect on the sta-
bility of HGF and circulation of injured tissue in which overgrowth
of bacteria might have caused intravascular obstruction and rap-
idly deteriorated circulation. Besides, HGF has also been shown
to inhibit platelet aggregation in vitro [26]. Appropriate antibiotic
treatment against underlying bacteria together with AT III and
HGF may have caused improved circulation.
It is known that blood products, including AT III, contain plas-
matic trace impurities. The beneﬁcial effect of AT III in critically
ill patients suffering from multiple organ deﬁciency has been an
area of investigation. However, there is a discrepancy between
study results. We have shown that AT III products contain a very
potent form of HGF. Effects on organ failure during sepsis and
regenerative properties of HGF have been reported [27]. Thus, this
should be given consideration in the studies of AT III reporting ben-
eﬁcial effects on organ failure during sepsis (Table 1). It is notewor-
thy that the AT III products which contained biologically active
HGF and that had beneﬁcial effects in the treatment of the patients
in this study were the ones that also showed the lowest risk ratio of
mortality as outcome after treatment in critically ill patients in the
review article by Afshari et al. Further studies, both in vitro and
comparing AT III with and without biologically active HGF in a
double-blind clinical study might be indicated.5. Conclusion
The reason for an acute inﬂammation that otherwise should
heal rapidly becoming chronic is not yet known. In the process of
chronic inﬂammation, inactivation of growth factors, such as
HGF, is seen and the application of HGF, with similar properties
as found in healthy subjects, supports the healings process. In
the present work commercial AT III products have been studied
regarding the presence and quality of HGF, and patients with crit-
ical, deep, chronic ulcer infections are treated locally with an AT III
product containing biologically active HGF. The outcome and fol-
low-up of patients indicate favorable results of the intervention.Acknowledgements
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